Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Antifungal susceptibility profile of Candida species and uncommon yeasts from drug abusers with oral candidiasis.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: BioMed Central Country of Publication: England NLM ID: 101088684 Publication Model: Electronic Cited Medium: Internet ISSN: 1472-6831 (Electronic) Linking ISSN: 14726831 NLM ISO Abbreviation: BMC Oral Health Subsets: MEDLINE
- Publication Information:
Original Publication: London : BioMed Central, [2001-
- Subject Terms:
- Abstract:
In Iran, there is limited information regarding the species distribution and antifungal susceptibility profiles of yeast isolates from drug addicts suffering from oral candidiasis (OC). In this study, 104 yeast isolates, including 98 Candida species and 6 uncommon yeasts, were collected from 71 drug abusers with OC. The susceptibility profiles of Candida spp. and uncommon yeasts to amphotericin B (AMB), itraconazole (ITC), nystatin (NYC), fluconazole (FLC), and caspofungin (CAS) were evaluated using the CLSI broth microdilution method. The prevalence of OC in the sampled population was found to be 29%. The susceptibility profile of Candida spp. revealed remarkable sensitivity, with 100% and 99% of isolates susceptible to NYC and AMB, respectively. However, concerning levels of resistance or non-wild-type minimum inhibitory concentrations (MICs) were observed, with 13.2% of Candida isolates showing resistance to FLC, 13.2% to ITC, and 16.3% to CAS. Notably, 35.2% of patients showed mixed yeast species, while 5.1% of Candida isolates exhibited multidrug resistance. The analysis of the uncommon yeast species showed that the overall frequencies of the highest MICs were observed for CAS. Furthermore, within the six non-Candida species identified, Hanseniaspora opuntiae and one isolate of Pichia kluyveri exhibited resistance to FLC and ITC, respectively, while all non-Candida species were susceptible to AMB and NYC. Additionally, one isolate of Pichia kluyveri exhibited simultaneously high MICs to two drugs ITC and CAS. Furthermore, the Hanseniaspora opuntiae isolate showed high MICs to CAS and FLC. The findings from the present study suggest that AMB and NYC can be suitable choices for empiric treatment of both common Candida species and uncommon yeast infections in substance abuse patients.
Competing Interests: Declarations. Ethics approval and consent to participate: The study protocol was approved by the Research Ethics Committee of Ahvaz Jundishapur University of Medical Sciences, with the ethical code number IR.AJUMS.MEDICINE.REC.1400.047. All participants in our study provided informed consent prior to their inclusion. The participants signed an informed consent form, and we adhered to all relevant guidelines and regulations throughout the study. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
(© 2024. The Author(s).)
- References:
J Clin Microbiol. 2017 Dec 26;56(1):. (PMID: 29070656)
Addict Health. 2021 Apr;13(2):106-113. (PMID: 34703531)
Oral Dis. 2020 Oct;26(7):1366-1374. (PMID: 31793130)
Mikrobiyol Bul. 2009 Apr;43(2):269-76. (PMID: 19621612)
J Med Microbiol. 2006 Feb;55(Pt 2):223-228. (PMID: 16434716)
Lett Appl Microbiol. 2023 Mar 1;76(3):. (PMID: 36921218)
Mater Sociomed. 2013 Dec;25(4):223-5. (PMID: 24511261)
Lett Appl Microbiol. 2016 Oct;63(4):254-9. (PMID: 27450704)
Adv Biomed Res. 2020 Sep 30;9:50. (PMID: 33457333)
Curr Med Mycol. 2015 Sep;1(3):11-16. (PMID: 28680991)
BMC Infect Dis. 2018 Jan 8;18(1):24. (PMID: 29310582)
Mycoses. 2017 Apr;60(4):273-279. (PMID: 28150341)
Curr Med Mycol. 2019 Mar;5(1):21-26. (PMID: 31049454)
Sci Rep. 2024 Jan 22;14(1):1906. (PMID: 38253731)
Microbiol Spectr. 2022 Jun 29;10(3):e0253921. (PMID: 35579442)
Arch Iran Med. 2010 Jul;13(4):282-7. (PMID: 20597560)
Addiction. 2019 Jan;114(1):150-166. (PMID: 30035835)
BMC Oral Health. 2023 May 5;23(1):262. (PMID: 37147684)
Med Mycol. 2013 Oct;51(7):737-46. (PMID: 23768242)
J Int Oral Health. 2015 Mar;7(3):20-3. (PMID: 25878473)
Antimicrob Agents Chemother. 2019 Jun 24;63(7):. (PMID: 30936110)
Antimicrob Agents Chemother. 2019 Jul 25;63(8):. (PMID: 31182537)
J Antimicrob Chemother. 2016 Jun;71(6):1438-50. (PMID: 26801081)
Adv Biomed Res. 2020 Jul 27;9:30. (PMID: 33072642)
J Fungi (Basel). 2020 Dec 29;7(1):. (PMID: 33383783)
ACS Infect Dis. 2021 Nov 12;7(11):2959-2970. (PMID: 34587737)
Lett Appl Microbiol. 2018 Oct;67(4):392-399. (PMID: 30019443)
Periodontol 2000. 2022 Oct;90(1):62-87. (PMID: 36183328)
Diagn Microbiol Infect Dis. 2019 Feb;93(2):112-119. (PMID: 30377018)
J Neuroimmune Pharmacol. 2011 Dec;6(4):442-65. (PMID: 21789507)
J Med Microbiol. 1987 May;23(3):275-7. (PMID: 3295247)
J Antimicrob Chemother. 2020 May 1;75(5):1194-1205. (PMID: 32025716)
Front Pediatr. 2021 Dec 24;9:805527. (PMID: 35004551)
Jpn J Infect Dis. 2005 Dec;58(6):344-8. (PMID: 16377864)
J Antimicrob Chemother. 2013 Jul;68(7):1660-8. (PMID: 23543609)
Curr Med Mycol. 2021 Sep;7(3):18-21. (PMID: 35528623)
Int J Drug Policy. 2020 Mar;77:102656. (PMID: 31951926)
Int J Health Plann Manage. 2019 Apr;34(2):e1323-e1333. (PMID: 31069871)
J Clin Microbiol. 2012 Nov;50(11):3641-51. (PMID: 22952266)
Rev Inst Med Trop Sao Paulo. 2012 Jan-Feb;54(1):17-24. (PMID: 22370749)
Front Microbiol. 2017 Mar 02;8:298. (PMID: 28303122)
- Contributed Indexing:
Keywords: Candida species; Antifungal resistance; Drug addiction; Oral candidiasis; Uncommon yeast species
- Accession Number:
0 (Antifungal Agents)
8VZV102JFY (Fluconazole)
304NUG5GF4 (Itraconazole)
1400-61-9 (Nystatin)
7XU7A7DROE (Amphotericin B)
F0XDI6ZL63 (Caspofungin)
0 (Echinocandins)
0 (Lipopeptides)
- Publication Date:
Date Created: 20241226 Date Completed: 20241226 Latest Revision: 20250104
- Publication Date:
20250104
- Accession Number:
PMC11673824
- Accession Number:
10.1186/s12903-024-05368-2
- Accession Number:
39725928
No Comments.